Alteogen signs up to 4.4 tln won deal with Novartis for subcutaneous formulations

Alteogen, a South Korean biotech, announced a licensing deal with Novartis valued up to 4.4 trillion won for subcutaneous formulations. The deal is a major commercial validation of Alteogen's technology platform, though financial terms and milestones are not fully disclosed. This is a significant corporate development for Alteogen, likely boosting its share price and signaling strength in the biotech sector.